Cancer Genetics Partners with Gilead on CLL Clinical Trials; Revises Expected Proceeds from IPO | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer Genetics today announced that Gilead Sciences has selected it to provide clinical trial services and molecular profiling of chronic lymphocytic leukemia patients.

Separately, the Rutherford, NJ-based cancer diagnostic company again lowered the anticipated net proceeds from its planned initial public offering.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.